Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra [Yahoo! Finance]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Yahoo! Finance
3 min read In This Article ANVS Annovis Bio, Inc. MALVERN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the filing of three new patents for innovative combination therapies involving its lead compound, buntanetap . These patents cover combinations of buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), or a combination of all three, creating a multifaceted approach to treating neurodegenerative diseases. Buntanetap , the Company's lead drug asset, inhibits the production of neurotoxic proteins and has been shown to improve cognition in early AD patients ( NCT05686044 ) and halt cognitive decline in PD patients ( NCT05357989 ). Recent preclinical studies have demonstrated that when buntanetap is combined with a GLP
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis To Present at the 2025 Annual Meeting of the Parkinson Study GroupGlobeNewswire
- Annovis Announces Two Presentations at the CTAD 2025 ConferenceGlobeNewswire
- Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease StudyGlobeNewswire
- Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's PatientsGlobeNewswire
- Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial ResultsGlobeNewswire
ANVS
Analyst Actions
- 9/30/25 - Canaccord Genuity
ANVS
Sec Filings
- 12/8/25 - Form 4
- 11/25/25 - Form 4/A
- 11/25/25 - Form 4
- ANVS's page on the SEC website